The TCRs Are Coming
It’s time to fine-tune the way we target solid tumors
Miguel Forte | | Opinion
In 2017, the industry shook with excitement at the news that the first CAR-T therapy, Kymriah, was approved for use by the FDA. The industry’s elation didn’t quieten quickly, as the approval of Yescarta came hot on its tails. But with time and room to think about the next step of the industry’s immunotherapy journey, many are beginning to consider how we can fine-tune treatments to better target solid tumors.
The recent clinical success seen in the CAR-T therapy space exemplifies the leaps in progress being made in the field, but such success has only been seen in a small number of tumor types. The selectivity of CAR-Ts for both tumor and normal cells also raises questions about whether they can (or will) adequately address cancer types beyond hematological malignancies, where tumor penetration is required.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.